Abnormalities in large scale functional networks in unmedicated patients with schizophrenia and effects of risperidone.
Abnormalities in large scale functional networks in unmedicated patients with schizophrenia and effects of risperidone.
复制标题
DOI：
10.1016/j.nicl.2015.11.015
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Lahti AC
中科院分区：
文献类型：
--
作者：
Kraguljac NV;White DM;Hadley JA;Visscher K;Knight D;ver Hoef L;Falola B;Lahti AC
描述未用药精神分裂症患者大规模功能网络的异常，并检查利培酮对网络的影响。34例未经药物治疗的精神分裂症患者和34例匹配的健康对照者参加了这项纵向研究。我们收集了静息状态下的功能磁共振成像数据与3T扫描仪在基线和六周后，他们开始使用利培酮。此外，一组19名健康对照者被扫描两次，间隔六周。四个大规模的网络，背注意网络，执行控制网络，显着性网络，默认模式网络的种子功能连接分析。组的连通性差异，以及随着时间的推移，连接的变化，进行了评估组的参与者水平的功能连接地图。在未经药物治疗的精神分裂症患者中，我们发现静息状态连接在背侧注意网络，执行控制网络和显着性网络中相对于对照参与者增加，但不是默认模式网络。治疗6周后，仅在背侧注意网络中，连接障碍减弱。该网络的基线连通性也与利培酮治疗6周时的临床应答相关。我们的研究结果表明，精神分裂症患者的大规模功能网络异常，利培酮仅在一定程度上调节，强调迫切需要开发新的抗精神病药物，通过减弱连接障碍来缓解症状。我们发现在未服药的精神分裂症患者中广泛存在功能性连接障碍。大规模功能网络在这种疾病中受到的影响似乎有所不同。利培酮仅在有限程度上减轻了连接障碍。
To describe abnormalities in large scale functional networks in unmedicated patients with schizophrenia and to examine effects of risperidone on networks. 34 unmedicated patients with schizophrenia and 34 matched healthy controls were enrolled in this longitudinal study. We collected resting state functional MRI data with a 3T scanner at baseline and six weeks after they were started on risperidone. In addition, a group of 19 healthy controls were scanned twice six weeks apart. Four large scale networks, the dorsal attention network, executive control network, salience network, and default mode network were identified with seed based functional connectivity analyses. Group differences in connectivity, as well as changes in connectivity over time, were assessed on the group's participant level functional connectivity maps. In unmedicated patients with schizophrenia we found resting state connectivity to be increased in the dorsal attention network, executive control network, and salience network relative to control participants, but not the default mode network. Dysconnectivity was attenuated after six weeks of treatment only in the dorsal attention network. Baseline connectivity in this network was also related to clinical response at six weeks of treatment with risperidone. Our results demonstrate abnormalities in large scale functional networks in patients with schizophrenia that are modulated by risperidone only to a certain extent, underscoring the dire need for development of novel antipsychotic medications that have the ability to alleviate symptoms through attenuation of dysconnectivity. We found widespread functional dysconnectivity in unmedicated patients with schizophrenia. Large scale functional networks appear differentially affected in the disorder. Attenuation of dysconnectivity with risperidone is seen only to a limited extent.